Spravato® (Esketamine) Treatment in Chesterfield, Virginia

Who Is Eligible for Spravato®?

Spravato® is approved for adults. It is not approved for anyone under 18.

Eligibility generally requires a diagnosis of treatment-resistant depression — depression that has not responded adequately to at least two antidepressants, each taken at an adequate dose for an adequate length of time during the current episode. That definition matters, and it is worth being precise about: a medication stopped after a week because of early side effects, or one never titrated to a therapeutic dose, does not usually count as an adequate trial. Part of the assessment is establishing what you have genuinely had a fair trial of.

Other factors affect eligibility. Blood pressure is assessed, because Spravato® can cause short-term increases; if your baseline blood pressure is elevated, the risks and benefits are weighed carefully. Your medical history, current medications, and any history of psychosis or substance misuse are all reviewed. Practical requirements matter too — you must be able to attend in person and arrange transport home after every session.

There is also a separate approved use, in conjunction with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour. Spravato® is not emergency treatment and does not replace emergency care.

If you are having thoughts of harming yourself right now, do not wait for an appointment. Call 911, go to your nearest emergency room, or call or text 988 to reach the Suicide & Crisis Lifeline.

Whether Spravato® is appropriate for you is determined by clinical assessment, not by a checklist online.

What Happens During a Spravato® Appointment

Most people want to know exactly what a session involves before committing. Here is the sequence.

Before Your Session

You will be given specific guidance on eating and drinking before your appointment, since nausea is a common effect. Follow it.

Your current medications are reviewed before each session, and your blood pressure is checked before dosing. Arrange transport home in advance — a friend, family member, or a rideshare or taxi service. You will not be able to drive yourself, and this applies to every session, not only the first.

Allow around two and a half to three hours on site. Bring something to occupy the monitoring period if you would like, though many people prefer to rest.

During Administration

You self-administer the nasal spray yourself, under the direct observation of a healthcare provider who confirms the dose is taken correctly. Administration itself takes only a few minutes.

Dosing is set by your clinician according to the treatment phase and your response. Vital signs are checked before administration and monitored afterwards, with blood pressure assessed at intervals through the session.

You remain in a quiet, comfortable treatment room throughout. You are not left alone.

The Monitoring Period

You are monitored on site for a minimum of two hours after each dose. This is a federal requirement under the SPRAVATO REMS program, not a practice preference, and it cannot be shortened at request.

During this period your blood pressure is checked at intervals, and respiratory status is monitored, including pulse oximetry. Most people experience some dissociation — a sense of detachment from yourself or your surroundings, altered perception of time, or a feeling that things seem unreal. It is disconcerting the first time and it is expected. Sedation and dizziness are also common. These effects typically begin shortly after dosing and settle within the monitoring window.

At the end of the monitoring period, a clinician assesses whether you are clinically stable before you leave. If you are not, monitoring continues. That judgement rests with the clinician.

After Your Session

You must not drive or operate machinery until the following day, after a restful night’s sleep. Your arranged transport takes you home.

Most people feel back to baseline the same evening. Plan a quiet afternoon rather than returning to work.

Report any side effects to the office, including anything that persists into the next day or anything that concerns you. Your response to each session informs the next one, so this feedback is clinically useful rather than a formality.

Treatment Schedule

Spravato® treatment runs in two phases.

During the induction phase, sessions are typically twice weekly for the first several weeks. This is the period in which response is established.

During the maintenance phase, frequency reduces — commonly to weekly, then to every two weeks, depending on response. The aim is the least frequent schedule that maintains benefit.

Therapeutic benefit is evaluated at the end of induction to decide whether continuing is appropriate. Schedules are individualized and set by your treating clinician, and the frequencies above are typical patterns rather than a fixed protocol.

The commitment is real and worth understanding before starting: twice-weekly sessions of two and a half to three hours, each requiring arranged transport, is a significant demand on work and family logistics for the first several weeks.

Risks and Side Effects

Spravato® carries FDA boxed warnings for sedation; dissociation; respiratory depression; abuse and misuse; and suicidal thoughts and behaviours. The REMS monitoring requirements exist specifically because of these risks.

Sedation, dissociation and respiratory depression. There is a risk of sedation, dissociation and respiratory depression following administration. This is why patients are monitored for at least two hours, including monitoring of respiratory status.

Abuse and misuse. Esketamine is a Schedule III controlled substance with potential for abuse and misuse. Your history is assessed before treatment and you are monitored during it.

Suicidal thoughts and behaviours. Antidepressants increased the risk of suicidal thoughts and behaviour in pediatric and young adult patients in short-term studies. All patients treated with antidepressants should be monitored closely for clinical worsening and the emergence of suicidal thoughts and behaviours. Spravato® is not approved for use in pediatric patients.

Common side effects include dissociation, dizziness, nausea, sedation, headache, altered taste, reduced sensitivity to touch, anxiety, increased blood pressure and vomiting.

Blood pressure. Spravato® can cause short-term increases in blood pressure, which is why it is measured before each dose and monitored afterwards. If your baseline blood pressure is elevated, the risks and benefits are weighed before proceeding.

This summary does not replace the full prescribing information. Read the complete FDA prescribing information, including the boxed warning and Medication Guide, and discuss any concerns with your clinician before starting treatment.

Insurance Coverage and Prior Authorization

Many commercial plans and Medicare cover Spravato®, but nearly all require prior authorization before treatment begins.

Insurers typically require documentation of your previous antidepressant trials — which medications, at what doses, for how long, and what the outcome was. This is the single most common reason authorizations are delayed, so gathering that history early helps considerably. Records from previous prescribers are worth requesting as soon as you begin considering treatment.

Our office assists with the prior authorization process and reviews expected costs with you before treatment starts. Billing usually involves both the medication and the administration and monitoring, which may appear as separate items.

If authorization is initially denied, that is not necessarily the end of it. Denials are frequently overturned on appeal with fuller documentation of treatment history.

For current coverage details and to begin benefits verification, contact the office.

Why Spravato® Requires an In-Person Visit

Spravato® must be administered in a certified healthcare setting. This is a requirement of the SPRAVATO REMS program — a federal risk management framework that restricts how the medication can be dispensed and administered.

Under the program, healthcare settings must be certified, the medication is dispensed and administered only within those settings, patients are enrolled in the program before treatment, administration is directly observed by a healthcare provider, and patients are monitored on site for at least two hours afterwards.

The practical consequence is that Spravato® cannot be prescribed by telehealth or collected from a pharmacy. Treatment is provided in person at our Chesterfield office at 9844 Lori Rd, Suite 100, serving patients across Chesterfield and Chesterfield County who are looking for Spravato® treatment near them. Certified treatment centres can also be located through the official Spravato® treatment centre locator.

Spravato® and Your Wider Treatment Plan

Spravato® is one component of treatment, not a replacement for the rest of it.

Depending on your clinical picture, it may be used as monotherapy or alongside an oral antidepressant, and it is provided within ongoing psychiatric care rather than as a standalone procedure. That means continued assessment of your treatment-resistant depression, ongoing medication management, and attention to sleep, physical health and daily functioning.

Individual psychotherapy is frequently part of the plan. Where Spravato® improves symptoms enough to make therapeutic work possible again, that combination is often where durable progress comes from.

Treatment begins with a comprehensive psychiatric evaluation, which establishes the diagnosis, reviews your full treatment history, and determines whether Spravato® is appropriate.

Frequently Asked Questions

What is Spravato®?

Spravato® is an FDA-approved esketamine nasal spray for adults with treatment-resistant depression, indicated as monotherapy or in conjunction with an oral antidepressant. It is administered only in a certified healthcare setting under the supervision of a clinician, and patients are monitored for at least two hours after each dose. It cannot be dispensed for use at home.

Who qualifies for Spravato® treatment?

Spravato® is approved for adults with treatment-resistant depression, generally meaning depression that has not responded adequately to at least two antidepressants taken at an adequate dose for an adequate length of time during the current episode. Eligibility also depends on your medical history, blood pressure and current medications. A clinical assessment is required to determine whether Spravato® is appropriate for you.

How long does a Spravato® appointment take?

Plan for approximately two and a half to three hours. Administration itself is brief, but federal REMS requirements mandate a minimum of two hours of monitoring afterwards, including blood pressure and respiratory checks, before you can leave.

Can I drive after a Spravato® session?

No. You must arrange transportation home after every session and must not drive or operate machinery until the next day, after a restful night’s sleep. This requirement applies to every appointment, not only the first.

What are the side effects of Spravato®?

The most common effects include dissociation, dizziness, nausea, sedation, headache and increased blood pressure. Spravato® carries FDA boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours. These risks, and the monitoring requirements that address them, are reviewed in full before treatment begins.

Is Spravato® covered by insurance in Virginia?

Many commercial plans and Medicare cover Spravato®, but nearly all require prior authorization with documentation of previous antidepressant trials. Coverage and out-of-pocket cost vary by plan. Sova Health Group assists with the prior authorization process and reviews expected costs with you before treatment begins.

Can Spravato® be prescribed through telehealth?

No. Under the SPRAVATO REMS program, esketamine must be administered in a certified healthcare setting with the patient monitored on site. Treatment is provided in person at the Chesterfield office, though preparatory consultations and follow-up psychiatric care may be available by telehealth.

Ask About Spravato® Treatment in Chesterfield

If two or more antidepressants have not worked for you, that does not mean you have run out of options — it means you meet the description of a condition with its own specific treatments.

The first step is an assessment to establish whether Spravato® treatment in Chesterfield, VA is appropriate for you. That conversation carries no obligation to proceed, and if Spravato® is not the right option, other approaches to treatment-resistant depression are discussed with you.

[Request a Spravato® eligibility consultation] · 9844 Lori Rd, Suite 100, Chesterfield, VA 23832 · (540) 277-9677